Skip to main content

Table 5 Cost-effectiveness results

From: Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina

Cost-effectiveness

MET + SU

MET + SAXA

Difference

Discounted costs

10,694,769 (10,694.8)

12,327,677 (12,327.7)

1,632,909 (1,632.9)

Discounted QALYs

9,322 (9.32)

9,544 (9.54)

221 (0.22)

Discounted LYG

20,765 (20.76)

20,845 (20.84)

80 (0.08)

Cost per QALY

  

7,374.2

Cost per LYG

  

20,490.3

  1. The number in brackets corresponds to the average value per patient.